ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

India's Modi government starts free COVID shots for all adults

Move speeds up process to reach goal of vaccinating 940m citizens by year-end

A man receives a vaccine shot in New Delhi on Feb. 13. The country began a free nationwide COVID-19 vaccination program for all adults on June 21.   © Reuters

NEW DELHI -- The government of Prime Minister Narendra Modi on Monday began no-cost COVID-19 vaccinations for all citizens over 18 years old -- about 940 million people. It also took over vaccine procurement from the states, which had been struggling to arrange doses for their own vaccination programs.

"From today, people aged 18 and above will get free vaccine under the Indian government campaign and the speed of the vaccination will also increase," Home Minister Amit Shah said during his visit to the western state of Gujarat. "It is a very big decision considering the huge population of the country," he said, appealing to the citizens to get their jabs as soon as possible.

India, a country of over 1.3 billion people, has set a target of vaccinating all of its adult population by the end of December. It is using two locally made vaccines -- Covishield, supplied elsewhere under the AstraZeneca label and manufactured by the Serum Institute of India; and Covaxin, developed by Indian drugmaker Bharat Biotech. Russia's Sputnik V vaccine has also been approved for emergency use.

"Whether it is poor, lower middle class, middle class, or upper class, only the free vaccines will be administered in the government of India campaign," Modi said earlier this month while announcing the new vaccination policy.

On the occasion of International Yoga Day on Monday, the prime minister underlined the importance of practicing yoga during the pandemic. "When the whole world is fighting the COVID-19 pandemic, yoga has become a ray of hope," he said. "When I talk to front-line warriors and doctors, they tell me that they have made yoga a protection shield against the coronavirus."

As part of the previous policy, the federal government provided free vaccines to front-line workers such as doctors, nurses and police personnel, along with citizens over age 45, while state governments were to buy shots on their own for people in the 18-44 age group. Many states had wanted to give free jabs to the 18-44 age group.

The federal government was procuring 50% of the total vaccines manufactured in India, while state governments and private hospitals were meant to secure 25% each. State governments had to compete with each other to get vaccines from manufacturers. They were also unhappy about the pricing.

The Serum Institute was selling Covishield to the federal government for 150 rupees ($2) per shot, while state governments were paying 300 rupees. Bharat Biotech was also selling Covaxin to the federal authorities for 150 rupees per dose, but charging states 400 rupees.

Now, under the revised policy, the Modi government has taken over the state-level procurement, which means it will buy 75% of the total doses produced locally and give them to states free of charge to vaccinate eligible people in all age groups.

"Those who do not want to get the vaccine for free [at government facilities] and want to get [it administered] at a private hospital have also been taken care of," Modi said on June 7, adding that the private hospitals will continue to procure 25% of the doses. However, those facilities can levy the maximum service charge of only 150 rupees per shot over the cost at which they procure the vaccine from manufacturers.

Private hospitals are buying vaccine doses at prices set by each manufacturer -- 600 rupees per dose for Covishield, 1,200 rupees for Covaxin and 948 rupees for Sputnik V.

The new vaccination guidelines "will lead to streamlining of the system ... and are expected to speed up the inoculation drive," India's top COVID-19 adviser V.K. Paul told a media briefing on Friday.

As of Friday, a total of 220.4 million people in India had received the first dose of the two-shot vaccine, while 50.3 million had received both doses.

Experts feel the revised vaccination policy will bring about uniformity in the system. "The centralized policy will lead to equitable distribution of vaccines nationwide now, which will benefit a large number of people," Rajinder K. Dhamija, head of the neurology department at Lady Hardinge Medical College and former WHO fellow at the National Institute of Epidemiology, told Nikkei Asia.

The new policy comes at a time when daily cases in India have dropped sharply, leading to easing of the lockdown restrictions. People have started thronging markets and train stations again and many can be seen defying social distancing rules, triggering fears that the country could face another serious wave of the pandemic.

From a high of over 400,000 daily cases in early May, when a deadly second wave of the pandemic ravaged the country, new infections have fallen below 100,000 per day. On Monday, India posted 53,256 new cases, the fewest in 88 days, bringing its total caseload to over 29.9 million, with 388,135 deaths.

"As we are gradually relaxing restrictions and resuming activities, we need to be cautious, as ... the virus is still around," Lav Agarwal, joint secretary in the health ministry, said on Friday. He added that people should still stay indoors as much as possible and go out only when necessary as well as wear masks and follow social distancing guidelines.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more